How quickly do you think hematologists will adopt the recently approved midostaurin for FLT3+ AML patients

How quickly do you think hematologists will adopt the recently approved midostaurin for FLT3+ AML patients

obr

3 years
274 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Aref Al-Kali, MD of Mayo Clinic discusses the approval of midostaurin for FLT3+ AML patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Up Next Autoplay